晚期非小细胞肺癌患者TKI靶向治疗与肿瘤组织EGFR基因突变的关系

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (467 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the relationship between tyrosine kinase inhibitor (TKI) targeting therapy and epithelial growth factor receptor (EGFR) gene mutation in patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 180 patients with NSCLC who received TKI targeted therapy from January 2015 to January 2017 in Guangyuan Center Hospital were retrospectively analyzed. All patients were pathologically confirmed as NSCLC, on all plasma samples from patients with EGFR mutation were detected before treatment, and then received TKI targeted therapy. The relationship between EGFR mutation and patient baseline data was analyzed, and the effect of EGFR mutation on the therapeutic effect of TKI targeted therapy and prognosis were discussed. Results A total of the 180 NSCLC patients, 118 were wild type and 62 were mutant, and the mutation rate was 34.44%. Sex, no smoking history, histology type were related to EGFR mutation (P ＜ 0.05); the other baseline data were not related to EGFR mutation (P ＞ 0.05). The EGFR mutant was higher than that of the EGFR wild type, and the difference was statistically significant (P ＜ 0.05). The 1 year survival rate of EGFR mutant patients was higher than that of EGFR wild type, and the difference was statistically significant (P ＜ 0.05). Conclusion The EGFR gene mutation in NSCLC patients is related to gender, no smoking history and histological type. EGFR mutant patients receiving TKI targeted therapy is better, which is beneficial to improve the 1 year survival rate of patients.

Key words： Non small cell lung cancer Tyrosine kinase inhibitor Epithelial growth factor receptor Mutation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Zheng1 LI Haijun1 CHEN Xiaoqin1 REN Jing1 ZHAO Shicai2

Cite this article:

ZHAO Zheng1 LI Haijun1 CHEN Xiaoqin1 REN Jing1 ZHAO Shicai2. The relationship between TKI targeting therapy and EGFR gene mutation in patients with advanced non-small cell lung cancer[J]. 中国医药导报, 2019, 16(10): 162-165.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I10/162

[1] 胡波，王道义.血小板和血浆纤维蛋白原水平与非小细胞肺癌转移及进展的相关研究[J].国际检验医学杂志，2015，36（2）：200-202.
[2] 田源，潘磊，徐国纲，等.老年非小细胞肺癌靶向治疗EGFR-TKI研究进展[J].老年医学与保健，2016，22（3）：140-143.
[3] 沈斌，张海兵，陈永朝，等.胸部精确放疗在Ⅳ期非小细胞肺癌寡转移患者的临床疗效[J].江苏医药，2017，43（11）：777-780.
[4] 霍婷婷，贾金虎.EGFR基因检测在非小细胞肺癌诊疗应用中的新进展[J].癌症进展，2016，14（6）：507-509.
[5] Tan DS，Yom SS，Tsao MS，et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-PositiveNon-Small Cell Lung Cancer：Status in 2016 [J]. J Thorac Oncol，2016，11（7）：946-963.
[6] 程小飞.晚期胃癌患者应用多西紫杉醇联合替吉奥与奥沙利铂联合替吉奥的临床疗效与化疗毒副反应比较[J].中国综合临床，2016，32（12）：1092-1095.
[7] Kuiper JL，Hashemi SM，Thunnissen E，et al. Non-classicEGFRmutations in a cohort of DutchEGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment [J]. Brit J Cancer，2016，115（12）：1504-1512.
[8] Yeh T，Jacobs V，Angell H，et al. 60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-nave EGFR mutant NSCLC patients treated with gefitinib（EGFR inhibitor）or gefitinib in combination with durvalumab（anti-PD-L1） [J]. J Thorac Oncol，2016，11（4）：S80-S81.
[9] Tian Y，Zhang Z，Miao L，et al. Anexelekto（AXL）Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells [J]. Oncol Res，2016，24（5）：295.
[10] Rosell R，Karachaliou N，Cui JJ，et al. P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor（TKI）Overcomes Innate Resistance in EGFR Mutant NSCLC [J]. J Thorac Oncol，2017，12（11）：S2230.
[11] 姚晓燕，申淑景，王晔，等.EGFR突变与非小细胞肺癌临床病理和TKI治疗疗效预测相关性分析[J].中华肿瘤防治杂志，2016，23（6）：369-372.
[12] Gray J，Okamoto I，Sriuranpong V，et al. OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC（FLAURA）：Plasma ctDNA Analysis [J]. J Thorac Oncol，2017，12（11）：S1754-S1755.
[13] Suda K，Rivard CJ，Mitsudomi T，et al. Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter [J]. Cancer Res，2016，76（10）：3109.
[14] 佘由，潘雪，邢玉斐，等.抗程序性死亡配体1单抗和表皮生长因子受体酪氨酸激酶抑制剂对表皮生长因子受体敏感突变肺癌细胞中程序性死亡配体1表达和T细胞功能的影响[J].中华肿瘤杂志，2016，38（12）：886-892.
[15] 董丹丹，刘卫平，唐源，等.即时定量PCR法和等位基因特异性寡核苷酸PCR法检测肺腺癌EGFR基因第21号外显子L858R突变的对比性研究[J].中华病理学杂志，2011，40（5）：338-340.
[16] 王志海，彭宗玉，杜国威，等.EGFR突变型转移性非小细胞肺癌的靶向治疗疗效及安全性[J].癌症进展，2017，15（7）：771-773.
[17] 姜海英，李艳芳，朱梅，等.EGFR-TKI一线治疗不同EGFR突变状态晚期非小细胞肺癌疗效分析[J].国际肿瘤学杂志，2017，44（1）：19-23.
[18] 虞倩，郭玮.数字PCR技术在NSCLC患者EGFR-TKI靶向治疗检测中的应用[J].中华检验医学杂志，2016， 39（3）：161-164.
[19] 苏鹏程，曹建忠，李红卫.EGFR突变NSCLC脑转移靶向治疗同步WBRT必要性研究[J].中华放射肿瘤学杂志，2016，25（8）：823-828.
[20] Hamaguchi R，Okamoto T，Sato M，et al. Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC [J]. Anticancer Res，2017，37（9）：5141-5145.